RxDoctor Payments Data

Yelena Anbinder

Psychiatric/Mental Health · Staten Island, NYNPI 1366959124

Payments from drug & device makers

$2,394in general payments, 2019–2025

Across 102 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$904
  • Otsuka America Pharmaceutical, Inc.$682
  • Lundbeck LLC$289
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • Almatica Pharma LLC$81
  • plus $248 from 6 others

What the payments were for

  • Food & beverage$2,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,394 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$221,051
Medicare patients
658
Services billed
2,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$51,410
VyvanseLisdexamfetamine Dimesylate11$3,607
Duloxetine Hcl116$1,971
Memantine Hcl ErMemantine Hcl19$1,273
Clonazepam200$1,269
Aripiprazole50$1,229
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$1,151
Buspirone Hcl74$925
Alprazolam186$900
Zolpidem Tartrate ErZolpidem Tartrate16$896
Bupropion XlBupropion Hcl67$894
Quetiapine Fumarate ErQuetiapine Fumarate20$684
Bupropion Hcl SrBupropion Hcl45$675
Escitalopram Oxalate118$645
Olanzapine29$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$682$51,41026 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$100$3,60711 claims
Almatica Pharma LLCSertraline Hcl$81$563153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →